Ultragenyx Pharmaceutical Newsroom

Express News | Ultragenyx Pharmaceutical: European Commission Extends Approval of Evkeeza to Children as Young as 6-Months Old With Hofh

Reuters02:08 ET

Denali Therapeutics Neurodegenerative Disease Platform Sparks Analyst Optimistic

BenzingaJan 3 13:08 ET

Insider Sale: President & CEO of $RARE (RARE) Sells 11,727 Shares

Quiver QuantitativeDec 31 14:15 ET

Ultragenyx Pharmaceutical Insider Sold Shares Worth $495,231, According to a Recent SEC Filing

MT NewswiresDec 31 14:11 ET

H.C. Wainwright Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Maintains Target Price $95

Moomoo NewsDec 24, 2024 06:31 ET · Ratings

Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE) and Springworks Therapeutics (SWTX)

TipRanksDec 24, 2024 06:20 ET · Ratings

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswireDec 20, 2024 16:30 ET

Express News | Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

ReutersDec 20, 2024 16:30 ET

Wells Fargo Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Raises Target Price to $88

Moomoo NewsDec 20, 2024 14:35 ET · Ratings

Wells Fargo Remains a Buy on Ultragenyx Pharmaceutical (RARE)

TipRanksDec 20, 2024 13:39 ET · Ratings

Evercore Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Maintains Target Price $70

Moomoo NewsDec 20, 2024 13:31 ET · Ratings

RARE Submits BLA to the FDA for Sanfilippo Syndrome Gene Therapy

Zacks Dec 20, 2024 10:35 ET

Express News | Wells Fargo Maintains Overweight on Ultragenyx Pharmaceutical, Raises Price Target to $88

BenzingaDec 20, 2024 08:38 ET

NHS England Rolls Out Evkeeza ▼(evinacumab) for Eligible Adults and Adolescents Aged 12 Years and Older With Homozygous Familial Hypercholesterolaemia (HoFH)

GlobeNewswireDec 20, 2024 03:00 ET

Express News | Ultragenyx Pharmaceutical Inc - Primary Endpoint Is Improvement in Cognition Assessed by Bayley-4

ReutersDec 19, 2024 16:06 ET

Express News | Ultragenyx Announces First Patient Dosed in Pivotal Phase 3 Aspire Study Evaluating Gtx-102 in Angelman Syndrome

ReutersDec 19, 2024 16:05 ET

Express News | Ultragenyx Submits Biologics License Application to the U.S. FDA for Ux111 Aav Gene Therapy for the Treatment of Sanfilippo Syndrome Type a (Mps Iiia)

ReutersDec 19, 2024 08:00 ET

Ultragenyx Submits Biologics License Application to the U.S. FDA for UX111 AAV Gene Therapy for the Treatment of Sanfilippo Syndrome Type A (MPS IIIA)

GlobeNewswireDec 19, 2024 08:00 ET

Express News | Ultragenyx Pharmaceutical Inc : Jefferies Cuts Target Price to $123 From $124

ReutersDec 17, 2024 01:05 ET

Barclays Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Maintains Target Price $81

Moomoo NewsDec 16, 2024 06:31 ET · Ratings